Mariel Marder

Dr. Mariel Marder

Química Biológica, FFyB, UBA-CONICET, Instituto de Química y Fisicoquímica Biológicas, Buenos Aires, Argentina
orcid

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2006 in European Journal of Pharmacology
Verified
Journal Article
Closed access
SFSebastián P. Fernández
Sebastián P. Fernández
CWCristina Wasowski
Cristina Wasowski
LLLeonardo M. Loscalzo
Leonardo M. Loscalzo
RGRenee E. Granger
Renee E. Granger
GJGraham A.R. Johnston
Graham A.R. Johnston
MMMariel Marder
Mariel Marder

1 May 2006 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
MCMariano Cárdenas
Mariano Cárdenas
MMMariel Marder
Mariel Marder
VBViviana C. Blank
Viviana C. Blank
LRLeonor P. Roguin
Leonor P. Roguin

1 April 1997 in Neurochemical Research
Verified
Journal Article
Closed access
PDF file
JMJorge H. Medina
Jorge H. Medina
HVHaydee Viola
Haydee Viola
CWClaudia Wolfman
Claudia Wolfman
MMMariel Marder
Mariel Marder
CWCristina Wasowski
Cristina Wasowski
APAlejandro C. Paladini
Alejandro C. Paladini

1 February 2004 in Pharmacology Biochemistry and Behavior
Verified
Journal Article
Closed access
SFSebastián Fernández
Sebastián Fernández
CWCristina Wasowski
Cristina Wasowski
APAlejandro C Paladini
Alejandro C Paladini
MMMariel Marder
Mariel Marder

1 June 2003 in Pharmacology Biochemistry and Behavior
Verified
Journal Article
Closed access
MMMariel Marder
Mariel Marder
HVHaydeé Viola
Haydeé Viola
CWCristina Wasowski
Cristina Wasowski
SFSebastián Fernández
Sebastián Fernández
JMJorge H Medina
Jorge H Medina
APAlejandro C Paladini
Alejandro C Paladini

13 May 2011 in Cell Death & Differentiation
Verified
Journal Article
Open access
PDF file
LPL A Pasquini
L A Pasquini
VMV Millet
V Millet
HHH C Hoyos
H C Hoyos
JGJ P Giannoni
J P Giannoni
Diego O. CrociDiego O. Croci
Diego O. Croci
JPJ M Pasquini
J M Pasquini
Galectins control critical pathophysiological processes, including the progression and resolution of central nervous system (CNS) inflammation. In spite of considerable progress in dissecting their role within lymphoid organs, their functions within the inflamed CNS remain elusive. Here, we investigated the role of galectin–glycan interactions in the control of oligodendrocyte (OLG) differentiation, myelin integrity and function. Both galectin-1 and -3 were abundant in astrocytes and microglia. Although galectin-1 was abundant in immature but not in differentiated OLGs, galectin-3 was upregulated during OLG differentiation. Biochemical analysis revealed increased activity of metalloproteinases responsible for cleaving galectin-3 during OLG differentiation and modulating its biological activity. Exposure to galectin-3 promoted OLG differentiation in a dose- and carbohydrate-dependent fashion consistent with the ‘glycosylation signature’ of immature versus differentiated OLG. Accordingly, conditioned media from galectin-3-expressing, but not galectin-3-deficient (Lgals3−/−) microglia, successfully promoted OLG differentiation. Supporting these findings, morphometric analysis showed a significant decrease in the frequency of myelinated axons, myelin turns (lamellae) and g-ratio in the corpus callosum and striatum of Lgals3−/− compared with wild-type (WT) mice. Moreover, the myelin structure was loosely wrapped around the axons and less smooth in Lgals3−/− mice versus WT mice. Behavior analysis revealed decreased anxiety in Lgals3−/− mice similar to that observed during early demyelination induced by cuprizone intoxication. Finally, commitment toward the oligodendroglial fate was favored in neurospheres isolated from WT but not Lgals3−/− mice. Hence, glial-derived galectin-3, but not galectin-1, promotes OLG differentiation, thus contributing to myelin integrity and function with critical implications in the recovery of inflammatory demyelinating disorders.